DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0155575 A1 Bai Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0155575 A1 Bai Et Al US 2014O155575A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0155575 A1 Bai et al. (43) Pub. Date: Jun. 5, 2014 (54) PROCESS OF PREPARING GUANYLATE (86). PCT No.: PCT/US 12/27287 CYCLASE CAGONSTS S371 (c)(1), (2), (4) Date: Feb. 11, 2014 (75) Inventors: Juncai Bai, North Augusta, SC (US); Related U.S. Application Data Ruoping Zhang, North Augusta, SC (US); Jun Jian, Shanghai (CN); Junfeng (60) Provisional application No. 61/447,891, filed on Mar. Zhou, Shanghai (CN); Qiao Zhao, 1, 2011. Shanghai (CN); Guoquing Zhang, Publication Classification Shanghai (CN); Kunwar Shailubhai, Audubon, PA (US); Stephen Comiskey, (51) Int. Cl. Doylestown, PA (US); Rong Feng, C07K 7/64 (2006.01) Langhorne, PA (US) C07K 7/08 (2006.01) (52) U.S. Cl. CPC. C07K 7/64 (2013.01); C07K 7/08 (2013.01) (73) Assignee: SYNERGY PHARMACEUTICALS USPC ........................................... 530/321:530/326 INC., New York, NY (US) (57) ABSTRACT (21) Appl. No.: 14/001,638 The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group (22) PCT Fled: Mar. 1, 2012 consisting of SEQID NOs: 1-249 described herein. Patent Application Publication Jun. 5, 2014 Sheet 1 of 3 US 2014/O155575A1 16d -aw C.CD N.5 CN OCD SRCD SNCN ( . CN C S O d. C-S V 3c : SS-$C O. htCD as hCD S.> a. N N N. NN C N. NN v N s i s Š : CN CN w- w (WM) peulee 9. Patent Application Publication Jun. 5, 2014 Sheet 2 of 3 US 2014/O155575A1 FIG. 2 Patent Application Publication Jun. 5, 2014 Sheet 3 of 3 US 2014/O155575A1 CY) O US 2014/0155575 A1 Jun. 5, 2014 PROCESS OF PREPARING GUANYLATE inflammatory bowel disease, with male and female patients CYCLASE CAGONSTS appearing to be equally affected. Most cases are diagnosed before age 30, but the disease can occur in the sixth, seventh, RELATED APPLICATIONS and later decades of life. 0001. This application claims the benefit of and priority to 0006 IBS and chronic idiopathic constipation are patho U.S. Provisional Application No. 61/447,891 filed on Mar. 1, logical conditions that can cause a great deal of intestinal 2011, the content of which is incorporated by reference in its discomfort and distress but unlike the inflammatory bowel entirety. diseases, IBS does not cause the serious inflammation or changes in bowel tissue and it is not thought to increase the FIELD OF THE INVENTION risk of colorectal cancer. In the past, inflammatory bowel disease, celiac disease, and IBS were regarded as completely 0002 The present invention relates to processes of prepar separate disorders. Now, with the description of inflamma ing guanylate cyclase C peptide agonists useful for the treat tion, albeit low-grade, in IBS, and of symptom overlap ment and prevention of various diseases and disorders. between IBS and celiac disease, this contention has come under question. Acute bacterial gastroenteritis is the strongest BACKGROUND OF THE INVENTION risk factor identified to date for the subsequent development 0003 Guanylate cyclase C is a transmembrane form of of postinfective irritable bowel syndrome. Clinical risk fac guanylate cyclase that is expressed on various cells, including tors include prolonged acute illness and the absence of Vom gastrointestinal epithelial cells (reviewed in Vaandrager 2002 iting. A genetically determined Susceptibility to inflamma Mol. Cell. Biochem. 230:73-83). It was originally discovered tory stimuli may also be a risk factor for irritable bowel as the intestinal receptor for the heat-stable toxin (ST) pep syndrome. The underlying pathophysiology indicates tides secreted by enteric bacteria and which cause diarrhea. increased intestinal permeability and low-grade inflamma The ST peptides share a similar primary amino acid structure tion, as well as altered motility and visceral sensitivity. Sero with two peptides isolated from intestinal mucosa and urine, tonin (5-hydroxytryptamine 5-HT) is a key modulator of gut guanylin and uroguanylin (Currie, et al., Proc. Nat'l Acad. function and is known to play a major role in pathophysiology Sci. USA 89:947-951 (1992); Hamra, et al., Proc. Nat 'l Acad. of IBS. The activity of 5-HT is regulated by c0MP. Sci. USA 90:10464-10468 (1993); Forte, L., Reg. Pept. 81:25 0007 While the precise causes of IBS and inflammatory 39 (1999); Schulz, et al., Cell 63:941-948 (1990); Guba, et al., bowel diseases (IBD) are not known, a disruption in the Gastroenterology 1 11:1558-1568 (1996); Joo, et al., Am. J. process of continual renewal of the gastrointestinal mucosa Physiol. 274:G633-G644 (1998)). may contribute to disease pathology in IBD and aggravate 0004. In the intestines, guanylin and uroguanylin act as IBS. The renewal process of the gastrointestinal lining is an regulators of fluid and electrolyte balance. In response to high efficient and dynamic process involving the continual prolif oral salt intake, these peptides are released into the intestinal eration and replenishment of unwanted damaged cells. Pro lumen where they bind to guanylate cyclase C localized on the liferation rates of cells lining the gastrointestinal mucosa are luminal membrane of enterocytes (simple columnar epithe very high, second only to the hematopoietic system. Gas lial cells of the small intestines and colon). The binding of the trointestinal homeostasis depends on both the proliferation guanylin peptides to guanylate cyclase C induces electrolyte and programmed cellular death (apoptosis) of epithelial cells and water excretion into the intestinal lumen via a complex lining the gut mucosa. Cells are continually lost from the intracellular signaling cascade that is initiated by an increase Villus into the lumen of the gut and are replenished at a in cyclic guanosine monophosphate (cGMP). substantially equal rate by the proliferation of cells in the 0005. The coMP-mediated signaling that is initiated by crypts, followed by their upward movement to the villus. The the guanylin peptides is critical for the normal functioning of rates of cell proliferation and apoptosis in the gut epithelium the gut. Any abnormality in this process could lead to gas can be increased or decreased in a variety of circumstances, trointestinal disorders such as irritable bowel syndrome (IBS) e.g., in response to physiological stimuli such as aging, and inflammatory bowel diseases. Inflammatory bowel dis inflammatory signals, hormones, peptides, growth factors, ease is a general name given to a group of disorders that cause chemicals and dietary habits. In addition, an enhanced pro the intestines to become inflamed, characterized by red and liferation rate is frequently associated with a reduction in Swollen tissue. Examples include ulcerative colitis and turnover time and an expansion of the proliferative Zone. The Crohn's disease. Crohn's disease is a serious inflammatory proliferation index is much higher in pathological states Such disease that predominantly affects the ileum and colon, but as ulcerative colitis and other gastrointestinal disorders. can also occur in other sections of the gastrointestinal tract. Intestinal hyperplasia is a major promoter of gastrointestinal Ulcerative colitis is exclusively an inflammatory disease of inflammation. Apoptosis and cell proliferation together regu the colon, the large intestine. Unlike Crohn's disease, in late cell number and determine the proliferation index. which all layers of the intestine are involved, and in which Reduced rates of apoptosis are often associated with abnor there can be normal healthy bowel in between patches of mal growth, inflammation, and neoplastic transformation. diseased bowel, ulcerative colitis affects only the innermost Thus, both increased proliferation and/or reduced cell death lining (mucosa) of the colonina continuous manner. Depend may increase the proliferation index of intestinal tissue, ing on which portion of the gastrointestinal tract is involved, which may in turn lead to gastrointestinal inflammatory dis Crohn's disease may be referred to as ileitis, regional enteri CaSCS. tis, colitis, etc. Crohn's disease and ulcerative colitis differ 0008. In addition to a role for uroguanylin and guanylinas from spastic colon or irritable bowel syndrome, which are modulators of intestinal fluid and ion secretion, these peptides motility disorders of the gastrointestinal tract. Gastrointesti may also be involved in the continual renewal of gastrointes nal inflammation can be a chronic condition. It is estimated tinal mucosa by maintaining the balance between prolifera that as many as 1,000,000 Americans are afflicted with tion and apoptosis. For example, uroguanylin and guanylin US 2014/0155575 A1 Jun. 5, 2014 peptides appear to promote apoptosis by controlling cellular amino acid units from position 1 through position 6 of SEQ ion flux. Given the prevalence of inflammatory conditions in ID NO: 1 or 9. In another embodiment, h is 7.j is 15, and k is Western societies a need exists to improve the treatment 16. More specifically, the first fragment has a sequence of options for inflammatory conditions, particularly of the gas amino acid units from position 15 through position 16 of SEQ trointestinal tract. ID NO: 1 or 9, the second fragment has a sequence of amino 0009 Peptide agonists of guanylate cyclase C agonists acid units from position 7 through position 14 of SEQID NO: (“GCC agonists”) are described in U.S. Pat. Nos. 7,041,786, 1 or 9, and the protected peptide produced via coupling the 7,799,897, and U.S. Patent Application Publication Nos. first and second fragments has a sequence of amino acid units US2009/0048175, US 2010/0069306, US 2010/0120694, US from position 7 through position 16 of SEQID NO: 1 or 9. In 2010/0093635, and US 2010/0221329. However, the solid one embodiment, the process of the invention further includes phase synthesis of peptides for pharmaceutical application deprotecting an amino group of the amino acid unitat position presents a number of special problems such as an overall low 7 of the protected peptide having the sequence of amino acid yield (e.g., less than 10%).
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Targeting the Deubiquitinase STAMBP Inhibits NALP7 Inflammasome
    ARTICLE Received 19 Jul 2016 | Accepted 8 Mar 2017 | Published 11 May 2017 DOI: 10.1038/ncomms15203 OPEN Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity Joseph S. Bednash1, Nathaniel Weathington1, James Londino1, Mauricio Rojas1, Dexter L. Gulick1, Robert Fort1, SeungHye Han1, Alison C. McKelvey1, Bill B. Chen1 & Rama K. Mallampalli1,2,3 Inflammasomes regulate innate immune responses by facilitating maturation of inflammatory cytokines, interleukin (IL)-1b and IL-18. NACHT, LRR and PYD domains-containing protein 7 (NALP7) is one inflammasome constituent, but little is known about its cellular handling. Here we show a mechanism for NALP7 protein stabilization and activation of the inflammasome by Toll-like receptor (TLR) agonism with bacterial lipopolysaccharide (LPS) and the synthetic acylated lipopeptide Pam3CSK4. NALP7 is constitutively ubiquitinated and recruited to the endolysosome for degradation. With TLR ligation, the deubiquitinase enzyme, STAM-binding protein (STAMBP) impedes NALP7 trafficking to lysosomes to increase NALP7 abundance. STAMBP deubiquitinates NALP7 and STAMBP knockdown abrogates LPS or Pam3CSK4-induced increases in NALP7 protein. A small-molecule inhibitor of STAMBP deubiquitinase activity, BC-1471, decreases NALP7 protein levels and suppresses IL-1b release after TLR agonism. These findings describe a unique pathway of inflammasome regulation with the identification of STAMBP as a potential therapeutic target to reduce pro-inflammatory stress. 1 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, UPMC Montefiore, NW 628, Pittsburgh, Pennsylvania 15213, USA. 2 Departments of Cell Biology and Physiology and Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. 3 Medical Specialty Service Line, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15240, USA.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Multiple Myeloma Inhibitory Activity of Plant Natural Products
    cancers Review Multiple Myeloma Inhibitory Activity of Plant Natural Products Karin Jöhrer 1 and Serhat Sezai Ҫiҫek 2,* 1 Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria; karin.joehrer@tkfi.at 2 Department of Pharmaceutical Biology, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany * Correspondence: [email protected] Simple Summary: Multiple myeloma is the second most common hematological cancer and is still incurable. Although enhanced understanding of the disease background and the development of novel therapeutics during the last decade resulted in a significant increase of overall survival time, almost all patients relapse and finally succumb to their disease. Therefore, novel medications are urgently needed. Nature-derived compounds still account for the majority of new therapeutics and especially for the treatment of cancer often serve as lead compounds in drug development. The present review summarizes the data on plant natural products with in vitro and in vivo activity against multiple myeloma until the end of 2020, focusing on their structure–activity relationship as well as the investigated pathways and involved molecules. Abstract: A literature search on plant natural products with antimyeloma activity until the end of 2020 resulted in 92 compounds with effects on at least one human myeloma cell line. Compounds were divided in different compound classes and both their structure–activity-relationships as well as eventual correlations with the pathways described for Multiple Myeloma were discussed. Each of the major compound classes in this review (alkaloids, phenolics, terpenes) revealed interesting candidates, such as dioncophyllines, a group of naphtylisoquinoline alkaloids, which showed pronounced Citation: Jöhrer, K.; Ҫiҫek, S.S.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • Late-Breaking Abstracts
    Late‐Breaking Abstracts ___________________________________________________________________ Late‐Breaking Abstracts Table of Contents Pg 2 Adaptive and Auto‐Immunity Abstracts LB708 – LB712 Pg 4 Carcinogenesis and Cancer Genetics Abstracts LB713 – LB715 Pg 6 Cell‐Cell Interactions in the Skin Abstracts LB716 – LB722 Pg 9 Epidermal Structure and Barrier Function Abstracts LB723 – LB730 Pg 13 Genetic Disease, Gene Regulation, and Gene Therapy Abstracts LB731 – LB735 Pg 15 Innate Immunity, Microbiology, and Microbiome Abstracts LB736 – LB740 Pg 18 Patient Population Research Abstracts LB741 – LB771 Pg 33 Patient‐Targeted Research Abstracts LB772 – LB782 Pg 39 Pharmacology and Drug Development Abstracts LB783 – LB795 Pg 45 Photobiology Abstracts LB796 – LB802 Pg 48 Pigmentation and Melanoma Abstracts LB803 – LB804 Pg 49 Skin of Color Abstracts LB805 ‐ LB806 Pg 50 Skin, Appendages, and Stem Cell Biology Abstracts LB807 Pg 51 Tissue Regeneration and Wound Healing Abstracts LB808 – LB811 Pg 53 Translational Studies Abstracts LB812 – LB823 Pg 59 Author Index Pg 65 Keyword Index 1 Adaptive and Auto-Immunity LB708 ILC1-like innate lymphocytes in human autoimmunity: Lessons from Alopecia Areata R. Laufer Britva1, A. Keren1, M. Bertolini2, R. Paus3, 4, A. Gilhar1 1Technion Israel Institute of Technology, Haifa, Haifa, Israel, 2Monasterium, Münster, Germany, 3Department of Dermatology & Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, United States, 4Dermatology Research Centre, University of Manchester, Manchester, Germany Innate lymphoid cells type 1 (ILC1) express NKG2D and produce large amounts of IFN-γ, i.e. two key elements in the pathogenesis of alopecia areata (AA). In this study, we aimed to explore a possible involvement of ILC1-like cells in human AA by using ex-vivo and in-vivo models for human AA.
    [Show full text]
  • {Replace with the Title of Your Dissertation}
    SYNTHESIS AND EVALUATION OF PARTHENOLIDE ANALOGUES: CHEMICAL PROBES AND THERAPEUTIC AGENTS A Thesis SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Dan Wang IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE Advisor: Dr. Daniel A. Harki MARCH 2013 © Dan Wang 2013 Acknowledgements I would like to begin by thanking my advisor, Dr. Dan Harki for his mentorship and support over these years. Your wisdom, knowledge and enthusiasm for science were a guiding light throughout my graduate school career. I wouldn’t be where I am without your vision, encouragement and advise. Additional thanks goes to Professor Rick Wagner, Professor Chengguo Xing and Professor Mark Distefano for serving on my dissertation committee, and for the helpful critiques and suggestions provided throughout my graduate career. Then, I would like to extend my sincere thanks to every past and present member of Harki group. Thank you all for the scientific help you have provided me all these years as well as being a constant source of support. In particular, Dr. Fred Meece for guiding me into the “parthenolide field” and Joe Hexum and Tim Andrew for providing some of the biological data in chapter 2. I would also like to thank and recognize my collaborators for all their assistance with regards to my projects. In particular, I would like to thank Professor David Largaespada, Sue Rathe and Zohar Sachs for their help and valuable discussion in primary AML cells; Professor John Ohlfest and Chani Becker for performing the brain tumor animal studies; Dr. Victor G. Young, Jr.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Localized Rnas Involves Silencing and Clustering After Transport Konstadinos Moissoglu1†, Kyota Yasuda1,2,3†, Tianhong Wang1†, George Chrisafis1, Stavroula Mili1*
    RESEARCH ARTICLE Translational regulation of protrusion- localized RNAs involves silencing and clustering after transport Konstadinos Moissoglu1†, Kyota Yasuda1,2,3†, Tianhong Wang1†, George Chrisafis1, Stavroula Mili1* 1Laboratory of Cellular and Molecular Biology,Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States; 2Program of Mathematical and Life Sciences, Graduate School of Integrated Science for Life, Hiroshima University, Higashi-Hiroshima, Japan; 3Laboratory for Comprehensive Bioimaging, RIKEN Center for Biosystems Dynamics Research, Suita, Japan Abstract Localization of RNAs to various subcellular destinations is a widely used mechanism that regulates a large proportion of transcripts in polarized cells. In many cases, such localized transcripts mediate spatial control of gene expression by being translationally silent while in transit and locally activated at their destination. Here, we investigate the translation of RNAs localized at dynamic cellular protrusions of human and mouse, migrating, mesenchymal cells. In contrast to the model described above, we find that protrusion-localized RNAs are not locally activated solely at protrusions, but can be translated with similar efficiency in both internal and peripheral locations. Interestingly, protrusion-localized RNAs are translated at extending protrusions, they become translationally silenced in retracting protrusions and this silencing is accompanied by coalescence of single RNAs into larger heterogeneous RNA clusters. This work describes a distinct mode of *For correspondence: translational regulation of localized RNAs, which we propose is used to regulate protein activities [email protected] during dynamic cellular responses. DOI: https://doi.org/10.7554/eLife.44752.001 †These authors contributed equally to this work Competing interests: The authors declare that no Introduction competing interests exist.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae Dr. Shyam S. Sharma Professor Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER) Sector 67, S.A.S. Nagar (Mohali) – 160062, Punjab, INDIA Email: [email protected]; [email protected] Dr Shyam S Sharma is a Professor in the Department of Pharmacology and Toxicology at the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India since 2009. Before joining NIPER Mohali, he worked as postdoctoral fellow at the University of Illinois at Chicago, USA and did his PhD (Pharmacology) at the All India Institute of Medical Sciences (AIIMS), New Delhi. Dr Sharma has published more than 150 peer reviewed research papers/patents/book chapters with more than 5000 citations, h-index 39, and i10-index 97 https://scholar.google.co.in/citations?user=yieVPfgAAAAJ&hl=en. His research interests includes understanding the potential role of pharmacological agents in CNS disorders (cerebral ischemia, Parkinson’s disease, Alzheimer’s disease), diabetic complications (neuropathic pain, cognitive impairment, cardiomyopathy), cardiovascular diseases, and safety pharmacology. He has more than 20 years of teaching (master’s and doctorate students) and research experience. Dr Sharma has guided more than 100 master’s and doctorate students. He has delivered more than 100 invited talks at national & international levels. He has completed more than 20 extramural and industry funded projects. He is recipient of Organisation for Pharmaceutical Producers of India (OPPI) Scientist Award, Shakuntala Amir Chand Prize and Dr D N Prasad Memorial Oration Award of Indian Council of Medical Research, CDRI Oration award, PP Suryakumari Prize and Prof.
    [Show full text]